Monoclonal antibodies in cancer therapy.
The need for improved specificity in cancer therapy is apparent. With the advent of monoclonal antibodies, the possibility of specifically targeted therapy is being considered. Early trials of monoclonal antibody in experimental animals and humans have indicated its ability to traffic to specific tumor sites and to localize on or around the tumor cells displaying antigens to which the antibody is directed. This evidence of specific targeting, along with preliminary evidence of therapeutic efficacy for monoclonal antibodies and immunoconjugates with drugs, toxins, and isotopes is encouraging. The current status of clinical trials with monoclonal antibodies is reviewed and an example of the experimental approach for the development of immunoconjugates in animal models is presented.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000276:immunology; D000918:Antibody Specificity; D002986:Clinical Trials as Topic; D006168:Guinea Pigs; D006801:Humans; D007116:Immunization, Passive; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm